Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...

Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...

Surgery Treatment of Glioblastoma Multiforme to Register a Double-digit Growth in next ten years, Fact.MR ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- The Glioblastoma Multiforme Treatment Market revenues were estimated at US$ 2.6 Bn in 2021 and is anticipated to grow at a CAGR of 10.1% from...

Investigation Report on China's Temozolomide Market 2021-2025 Featuring Merck Sharp & Dohme, Jiangsu Tasly Diyi Pharma, Beijing Shuanglu Pharma, Schering-Plough, Jiangsu Hengrui Medicine Co Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Temozolomide Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The sales value of...

Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...